ASH 2017 Annual Meeting Highlights in Multiple Myeloma

Please Log In or Register to continue.

Release Date: December 21, 2017
Expiration Date: December 21, 2018

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, participants will hear key highlights of several significant scientific updates in multiple myeloma (MM), presented at the 2017 American Society of Hematology (ASH) Annual Meeting. Leading experts in the field of MM will share their insights on a variety of abstracts, covering topics including, but not limited to: immunotherapy, proteasome inhibitors, minimal residual disease, predictive biomarkers, and novel agents. Don’t miss this opportunity to see how the future of treatment in multiple myeloma is continuing to evolve, and how these changes may positively impact patient outcomes.

  • Key ASH Takeaways, Plus Daratumumab in the Relapsed/Refractory Setting
  • Anti-BCMA CAR-T Cell Therapy in RRMM and RVd Lite in Transplant Ineligible MM
  • Monotherapy GSK2857916, an Anti-BCMA Antibody in RRMM
  • Ixazomib in the Maintenance Setting
  • Future Treatments in RRMM: Isatuximab and Melflufen
  • Highlights from the ASPIRE and PETHEMA/GEM2012 Trials

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with multiple myeloma (MM)
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in MM
  • Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in MM

Agenda

The activity includes six video sections which cover the following topic areas and abstracts:

  • Key ASH Takeaways, Plus Daratumumab in the Relapsed/Refractory Setting Sagar Lonial, MD, FACP
    • Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study (1869)
    • Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius (3107)
    • Key Educational Message this Year at ASH in the Changing Treatment Landscape for Multiple Myeloma
    • Practice-changing Trials to Watch in 2018

  • Anti-BCMA CAR-T Cell Therapy in RRMM and RVd Lite in Transplant Ineligible MM Noopur Raje, MD
    • Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy (740)
    • Final Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd lite) in Transplant-Ineligible Multiple Myeloma (3126)

  • Monotherapy GSK2857916, an Anti-BCMA Antibody in RRMMAdam D. Cohen, MD
    • Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159 (741)

  • Ixazomib in the Maintenance Setting Robert Z. Orlowski, MD, PhD
    • Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma (437)
    • Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies (902)

  • Future Treatments in RRMM: Isatuximab and Melflufen Paul G. Richardson, MD
    • Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM) (1887)
    • First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM) (3150)

  • Highlights from the ASPIRE and PETHEMA/GEM2012 TrialsJesús San Miguel, MD, PhD
    • Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial (743)
    • Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial (905)

Instructions for Participation and Credit

This activity is eligible for credit through December 21, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Adam D. Cohen, MD
Director, Myeloma Immunotherapy
Assistant Professor, Hematology/Oncology Division
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania

Dr. Adam Cohen received his medical degree from the University of Pennsylvania, Philadelphia, where he also completed an internal medicine residency. He then completed a hematology/oncology fellowship, and was a research associate in the Laboratory of Tumor Immunology at Memorial Sloan-Kettering Cancer Center, New York. Dr. Cohen is currently Director of Myeloma Immunotherapy and Assistant Professor of Hematology/Oncology at Abramson Cancer Center of the University of Pennsylvania.

Dr. Cohen is board certified in internal medicine, medical oncology, and hematology. He is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and the American Society of Hematology. He is also a member of the Multiple Myeloma Committee, Eastern Cooperative Oncology Group, and has served on the Multiple Myeloma Panel, National Comprehensive Cancer Network. In addition, Dr. Cohen is an ad hoc reviewer for several journals, including Leukemia, Blood, Amyloid, and Clinical Cancer Research. He has co-authored over 50 original articles, book chapters, and reviews on DNA vaccines, tumor immunity, multiple myeloma, amyloidosis, and stem cell transplant.

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is the Department Chair for Hematology and Medical Oncology at Emory University.

Dr. Lonial serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the Board of Directors for the International Myeloma Society and on the Scientific Advisory Board for the International Myeloma Foundation. Dr. Lonial is the myeloma editor for Clinical Lymphoma and Myeloma and is on the editorial board for the Journal of Clinical Oncology. He is also an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, Leukemia, and other journals, and has authored or co-authored over 200 papers and abstracts.

Dr. Lonial has worked in the field of immunotherapy and cancer, and has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway and the role of 14-3-3 in proteasome function.

Robert Z. Orlowski, MD, PhD
Professor, Chair Ad Interim
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Robert Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University, St. Louis School of Medicine. Dr. Orlowski is a Professor and Chair Ad Interim in the Department of Lymphoma/Myeloma, and Professor in the Department of Experimental Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Board-certified in internal medicine and medical oncology, Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy with a focus on the pathogenesis of oncologic disease and mechanisms of action of chemotherapeutics. In addition, he is a reviewer for several journals, including Blood, Cancer Research, Journal of Clinical Oncology, and The New England Journal of Medicine. His clinical research efforts focus on novel clinical trials for patients with hematologic malignancies.

Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University in India. She trained in internal medicine at Massachusetts General Hospital (MGH), and subsequently completed a fellowship in hematology and medical oncology in the joint Mass General-Brigham & Women’s-Dana-Farber program. She is a Professor of Medicine at Harvard Medical School and the Rita M. Kelley Chair in Oncology at MGH.

Dr. Raje is a physician scientist with a focus on the development of innovative therapies for multiple myeloma. As Director of the Center for Multiple Myeloma at the MGH Cancer Center, she leads a dedicated clinical team engaged in investigator-initiated, multicenter national and international clinical trials, all aimed at developing new promising therapies for this disease. She also leads translational efforts at MGH with her laboratory's efforts focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and whose targeting may result in improved therapeutic outcomes. Dr. Raje is the recipient of numerous awards including the Multiple Myeloma Senior Research Award, The Leukemia and Lymphoma Society Clinical Scholar Award and the Claflin Distinguished Scholar Award.

Paul G. Richardson, MD
R.J. Corman Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Paul Richardson received his medical degree from the Medical College of St. Bartholomew's Hospital, University of London, and was chief resident at the Royal Marsden Hospital, London. After a clinical fellowship at Baystate Medical Center of Tufts University School of Medicine, he joined Dana-Farber Cancer Institute (DFCI). Dr. Richardson spent five years with the Solid Tumor Autologous Marrow Program, completed a medical residency at Beth Israel Hospital, and joined DFCI’s Jerome Lipper Multiple Myeloma Center, becoming Clinical Director and most recently, Clinical Program Leader and Director of Clinical Research.

Jesús San Miguel, MD, PhD
Professor of Medicine-Hematology 
Director of Clinical and Translational Medicine
University of Navarra
Navarra, Spain

Dr. Jesús San Miguel is Professor of Medicine-Hematology and Director of Clinical and Translational Medicine at the University of Navarra in Spain. He served as Director of the Hematology Department of the University Hospital of Salamanca in Spain for more than 22 years (1991-2013). Dr. San Miguel is currently President of the International Myeloma Society and a member of the Advisory Board of the International Myeloma Foundation and the Multiple Myeloma Research Foundation. In addition, he has served as board councillor for the European Association, chairman of the Scientific Committee for the IXth Congress (2004), president of the 15th European Hematology Association (EHA) Congress, and was associate editor for Blood and Haematologica.

Dr. San Miguel has published more than 780 original papers in international journals. He has made important contributions to myeloma cell biology in immunophenotyping, risk of progression from monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (MM) into active MM, and minimal residual disease, as well as in therapeutics, including studies for new antimyeloma drugs at the preclinical and clinical levels, which include proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and histone deacetylases (HDACs). Dr. San Miguel has received numerous awards, including the Waldenström Award, EBMT Lecture, Celgene Career Achievement Award, Kyle Lifetime Achievement Award, Jose Carreras EHA Award, Ham-Wasserman Lecture Award, Rey Jaime I Award in Clinical Medicine, and the Spanish Prizes in both oncology and translational research.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-17-180-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 17-180-069

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Adam Cohen has received honoraria related to formal advisory activities from Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., and Seattle Genetics, Inc. He has received grant support related to research activities from Bristol-Myers Squibb and Novartis AG.

Dr. Sagar Lonial has received honoraria related to formal advisory activities from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, and Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb, Celgene, and Takeda Oncology.

Dr. Robert Orlowski has received honoraria related to formal advisory activities from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Kite Pharma, sanofi-aventis U.S. LLC., and Takeda Oncology. He has received grant support related to research activities from Amgen, BioTheryX, Inc., and Spectrum Pharmaceuticals, Inc.

Dr. Noopur Raje has received honoraria as a consultant from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, and Takeda Oncology. She has received grant support related to research activities from AstraZeneca.

Dr. Paul Richardson has received honoraria as a consultant from Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, and Takeda Oncology.

Dr. Jesús San Miguel has received has received honoraria related to formal advisory activities from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Novartis AG, Sanofi, and Takeda Oncology.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.